# ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2025
Canonical URL: https://biopharmsignal.com/news/ICCC/immucell-to-announce-unaudited-financial-results-for-the-quarter-and-year-ended--cf3bd63e
Ticker: ICCC
Company: ImmuCell
Source: ImmuCell
Published: 2026-02-18 13:37 EST
## Summary

Conference Call Scheduled for Thursday, March 5, 2026 at 9:00 AM ET February 18, 2026 08:37 ET | Source: ImmuCell Corporati...

## Article Body
Conference Call Scheduled for Thursday, March 5, 2026 at 9:00 AM ET

February 18, 2026 08:37 ET | Source: ImmuCell Corporation

PORTLAND, Maine, Feb. 18, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health company that develops, manufactures and markets products that improve cattle health and productivity, expects to report unaudited financial results for the quarter and year ended December 31, 2025 after the market closes on Wednesday, March 4, 2026.

The Company is planning to host a conference call the next morning, Thursday, March 5, 2026, at 9:00 AM ET to review the unaudited financial results. Interested parties can access the conference call by dialing (844) 855-9502 (toll free) or (412) 317-5499 (international) at 9:00 AM ET. A teleconference replay of the call will be available until March 12, 2026 at (855) 669-9658 (toll free) or (412) 317-0088 (international), utilizing replay access code #2017737.

The Company anticipates no change to the preliminary sales results for the quarter and year ended December 31, 2025 that were disclosed on January 8, 2026. The Company expects to file its Annual Report on Form 10-K on or before Tuesday, March 31, 2026.

About ImmuCell: ImmuCell Corporation's ( Nasdaq: ICCC ) purpose is to create scientifically proven and practical products that improve cattle health and productivity. ImmuCell manufactures and markets First Defense ® , providing Immediate Immunity ™ to newborn dairy and beef calves. Press releases and other information about the Company are available at: http://www.immucell.com .

| Contacts: | Olivier te Boekhorst, President and CEO |
| --- | --- |
|  | Timothy C. Fiori, Chief Financial Officer |
|  | ImmuCell Corporation |
|  | investor.relations@immucell.com |
|  | Joe Diaz, Robert Blum and Joe Dorame |
|  | Lytham Partners, LLC |
|  | iccc@lythampartners.com |
## Recent Company News
- 2026-07-09 20:05 EST — [ImmuCell Announces a 12% Increase in Product Sales in Q2 of 2026 and a 21% Increase in the First Six Months of 2026, Based on Preliminary, Unaudited Sales Results](https://biopharmsignal.com/news/ICCC/immucell-announces-a-12-increase-in-product-sales-in-q2-of-2026-and-a-21-increas-9613a4a9) — Source: ImmuCell
- 2026-05-14 20:05 EST — [ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2026](https://biopharmsignal.com/news/ICCC/immucell-announces-unaudited-financial-results-for-the-quarter-ended-march-31-20-d73ca2ba) — Source: ImmuCell
- 2026-05-07 20:05 EST — [ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2026](https://biopharmsignal.com/news/ICCC/immucell-to-announce-unaudited-financial-results-for-the-quarter-ended-march-31--4b91433e) — Source: ImmuCell
- 2026-04-13 20:38 EST — [ImmuCell Bolsters its Innovation Strategy with Appointments of Dr. Gilles Guillemette and Dr. Anthony DiMarco to the Board, and Moves to a Smaller Board of Independent Directors](https://biopharmsignal.com/news/ICCC/immucell-bolsters-its-innovation-strategy-with-appointments-of-dr-gilles-guillem-0dff31ee) — Source: ImmuCell
- 2026-04-08 20:05 EST — [ImmuCell Announces a 28.4% Increase in Product Sales in Q1 of 2026, based on Preliminary, Unaudited Sales Results](https://biopharmsignal.com/news/ICCC/immucell-announces-a-28-4-increase-in-product-sales-in-q1-of-2026-based-on-preli-34032873) — Source: ImmuCell
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)